{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T19:46:50Z","timestamp":1762458410794},"reference-count":8,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[1985,9,1]],"date-time":"1985-09-01T00:00:00Z","timestamp":494380800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[1985,9]]},"DOI":"10.1007\/bf00431773","type":"journal-article","created":{"date-parts":[[2004,11,11]],"date-time":"2004-11-11T04:25:45Z","timestamp":1100147145000},"page":"30-33","source":"Crossref","is-referenced-by-count":18,"title":["Early unwanted effects of fluphenazine esters related to plasma fluphenazine concentrations in schizophrenic patients"],"prefix":"10.1007","volume":"87","author":[{"given":"A. C.","family":"Altamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. H.","family":"Curry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. H.","family":"Wiles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"CR1","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/bdd.2510010204","volume":"1","author":"AC Altamura","year":"1979","unstructured":"Altamura AC, Whelpton R, Curry SH (1979) Animal model for fluphenazine kinetics after administration of long-acting esters. Biopharmaceutics and Drug Disposition 1:65?72","journal-title":"Biopharmaceutics and Drug Disposition"},{"key":"CR2","first-page":"10","volume":"271s","author":"M Asberg","year":"1978","unstructured":"Asberg M, Montgomery S, Perris C, Schalling D, Sedvall G (1978) The Comprehensive Psychopathological Rating Scale. Acta Psychiatr Scand 271s:10?27","journal-title":"Acta Psychiatr Scand"},{"key":"CR3","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(79)90749-9","volume":"1","author":"SH Curry","year":"1979","unstructured":"Curry SH, Altamura AC, Montgomery SA (1979b) Unwanted effects of enanthate and decanoate. Lancet 1:331?332","journal-title":"Lancet"},{"key":"CR4","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2125.1979.tb00941.x","volume":"7","author":"SH Curry","year":"1979","unstructured":"Curry SH, Whelpton RW, de Schepper PJ, Vranckx S, Schiff AA (1979a) Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man. Br J Clin Pharmacol 7:325?331","journal-title":"Br J Clin Pharmacol"},{"key":"CR5","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1176\/ajp.135.7.883","volume":"135","author":"J Kane","year":"1978","unstructured":"Kane J, Quitlain F, Rifkin A, Klein DF (1978) Comparison of the incidence and severity of extrapyramidal side effects with fluphenazine enanthate and fluphenazine decanoate. Am J Psychiatr 135:1539?1542","journal-title":"Am J Psychiatr"},{"key":"CR6","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/S0033-3182(69)71790-X","volume":"10","author":"A Keskiner","year":"1969","unstructured":"Keskiner A, Itil TM, Holden JMC (1969) Fluphenazine enanthate and decanoate: a comparative study in chronic schizophrenic out-patients. Psychosomatics 10:42?45","journal-title":"Psychosomatics"},{"key":"CR7","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1111\/j.1365-2125.1979.tb01045.x","volume":"8","author":"DH Wiles","year":"1979","unstructured":"Wiles DH, Gelder MG (1979) Plasma fluphenazine levels by radio-immunoassay in schizophrenic patients treated with depot injections of fluphenazine decanoate. Br J Clin Pharmacol 8:565?570","journal-title":"Br J Clin Pharmacol"},{"key":"CR8","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1017\/S0033291700015841","volume":"6","author":"DH Wiles","year":"1976","unstructured":"Wiles DH, Kolakowska T, McNeilly AS, Mandelbroke BM, Gelder MG (1976) Clinical significance of plasma chlorpromazine levels. I. Plasma levels of the drug some of its metabolites and prolactin during acute treatment. Psychol Med 6:407?415","journal-title":"Psychol Med"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00431773.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF00431773\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF00431773","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,4,9]],"date-time":"2019-04-09T22:39:44Z","timestamp":1554849584000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF00431773"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1985,9]]},"references-count":8,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1985,9]]}},"alternative-id":["BF00431773"],"URL":"https:\/\/doi.org\/10.1007\/bf00431773","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[1985,9]]}}}